
zzso zzso offers a unique treatment zzso for prostate cancer, especially stages that are resistant to current therapies, with the additional benefit of zzso targeting tumor cells amongst an environment of healthy zzso zzso the low zzso zzso zzso zzso zzso as well as a zzso zzso of zzso zzso zzso and zzso 1 zzso are evaluated as novel zzso agents against human prostate zzso 

The surface expression of viral receptors required for zzso cell zzso including zzso zzso zzso zzso zzso factor zzso and zzso zzso on a number of human prostate cancer lines was assessed by flow zzso zzso to viral zzso was determined via in zzso cell zzso zzso performed on cell zzso cultured in zzso zzso zzso The in zzso zzso efficacy of the zzso was assessed using zzso models in immune compromised zzso following systemic zzso 

The majority of prostate cancer lines tested expressed surface zzso and/or zzso or zzso zzso significant degrees of zzso following in zzso viral zzso zzso delivery of each of the three viruses induced reduction of zzso tumor burdens in zzso and a therapeutic zzso was demonstrated for escalating doses of EV1 in the zzso animal zzso 

zzso zzso zzso and EV1 are potentially potent zzso agents against human prostate zzso 

